Advanx Technology Pte Ltd

[Jacinto Man]

On14th August 2020, Leave a Nest Malaysia Sdn. Bhd. signed an agreement with Advanx Health at Nest-Bio Venture Lab (NBVL), MJIIT-UTM, Kuala Lumpur. Advanx Health is the first Malaysian biotech startup to join Nest-Bio Venture Lab.

The agreement was signed by Mr. Abdul Hakim Sahidi, Managing Director of Leave a Nest Malaysia Sdn. Bhd. and Mr. Yong Wei Shian, Founder and CEO of Advanx Health in the presence of Assoc. Prof. Dr. Hirofumi Hara, Head of Memo-Bio iKohza, MJIIT-UTM.

Advanx Health was founded in February 2018 by Mr. Yong Wei Shian. Advanx Health is a team of healthcare professionals that combine genetic data and lifestyle to help Malaysians to understand more about themselves. Advanx Health also provides a platform that allows customers to engage with providers of different solutions after receiving their health report. The reason why Advanx Health chose NBVL is because of its perfect location (centre of Kuala Lumpur), complete equipment, and high-end facilities. The collaboration with Leave a Nest Malaysia Sdn. Bhd. will support the development of an in-house system for Advanx Health.

Leave a Nest Malaysia Sdn. Bhd. together with MJIIT-UTM would like to position NBVL to be the place where it can nurture more biotech startups and bridge them to international partners especially from Japan.

Nest-Bio Venture Lab was a joint venture lab between Leave a Nest Malaysia Sdn. Bhd. and Malaysia-Japan International Institute of Technology (MJIIT), Universiti Teknologi Malaysia (UTM). NBVL will have an incubator for biotechnology startups and incubatees will have the privilege to use the lab space, access to one of a kind, high-end machines such as Next Generation Sequencing (NGS) machine, and obtain expert consultations from MJIIT, UTM. Two successful biotechnology startups from Japan, euglena Co., Ltd. and Metabologenomics, Inc. (Metagen) have agreed to participate as premier international partners for NBVL. The collaboration is also to support the grooming of effective science communication skills among postgraduate candidates through human resource training. Apart from that, Leave a Nest Malaysia Sdn. Bhd. and MJIIT, UTM will develop and conduct educational programs such as science workshops for young researchers from secondary and primary schools in the near future.

Every cell in our body contains a copy of our genome. The human genome comprises over 20,000 genes and three billion letters of DNA. Human DNA consists of two strands, twisted into a double helix and held together by a simple pairing rule (A pairs with T, and G pairs with C).

Our genes shape who we are as individuals and an intelligent species. Genes also have a profound effect on human health. Thanks to the advances in DNA sequencing technology, scientists have discovered thousands of genes that affect our disease risk. To understand how genes work, express, and eventually affect our complex biological system, scientists need ways to control and study them.

Manipulating genes in living cells is not easy. However, a recent advance in molecular sciences has developed a new method- The CRISPR-Cas9 genome editing system. This invention promises to dramatically improve our ability to edit the DNA of any species, including human2.

CRISPR-Cas9 is a powerful molecular system. It enables scientists to edit part of the genome by deleting, inserting or replacing letters of the DNA sequence.

Its application is currently recognised as the cheapest, most straightforward, versatile and precise method of genetic engineering. Therefore, it prompted a phenomenal response in the science world.

The development of the CRISPR-Cas9 system is based on the natural immune system used by bacteria to protect themselves from virus infection.

When a bacterium detects virus DNA, it snips out and integrates parts of the virus DNA and into its genome. This creates a memory record that can help them recognise and defend against the second virus infection by producing guide RNA (gRNA). The gRNA contains a sequence that matches that of the violating virus DNA.

This gRNA forms a complex with Cas9 protein. When the gRNA matches and binds the virus DNA, it instructs the Cas9 protein to cut the virus DNA and eventually disable the virus infection.

Over the past few years, scientists studied the natural system and noticed that it could be programmed to cut not just the virus DNA but any DNA sequence. It can cut DNA at a precisely chosen location by designing and modifying the gRNA.

The designed gRNA contains letters that are complementary to the target DNA, like certain functional genes.

In order words, the designed RNA will only bind specifically to the target DNA and no other regions of the genome2,3.

This system is applicable not just in a test tube but also within the nucleus of a living cell.

Once inside the nucleus, the effector CRISPR-Cas9 complex will find and lock onto a short sequence of the targeted DNA known as the PAM.

Upon locking, the Cas9 protein will unzip the double helix DNA and match it to the gRNA.

After the matching completes, gRNA guides Cas9 to cut DNA at the precise location by using its two tiny molecular scissors.

The cutting process leaves a break in the double-stranded DNA, and the cell can detect and repair the break.

Upon detection, the cell will paste both broken ends together with little changes in the sequence of that position.

The cell might also integrate a new piece of DNA at the cut site.

Scientists leverage the DNA repair machinery to introduce new genes or replace defective genes with desirable ones.

CRISPR-Cas9 is notable for its ability to treat a wide range of genetic diseases. Some of which are the result of a single incorrect nucleotide in DNA.

However, the CRISPR-Cas9 system can precisely replace the single nucleotide error. This can terminate genetic diseases such as Down syndrome, Patau syndrome, Tay-Sachs disease, cystic fibrosis, and haemophilia6.

Apart from that, cancer cells that abnormally multiply while overpassing the immune response is always a big trouble.

However, an injection of CRISPR programmed immune cells can potentially target a specific cancer cell from concealing, such as lung cancer1.

Many of the applications involve the genome editing of non-reproductive cells. Nevertheless, genome programming of reproductive cells such as sperm and ovum triggers a public outcry.

This is because any genome editing in reproductive cells will be passed on from generation to generation, and it prompts ethical implications4. Therefore, genome editing in reproductive cells is illegal and prohibited in the science world.

In parallel with the COVID-19 pandemic, a new version of the CRISPR-Cas13 system is proposed5,8. The programmed gRNA in this system targets the viral RNA genome of the SARS CoV-2 virus.

The Cas13 protein recognises the single-stranded viral RNA and cuts the RNA sequence at a specific location.

It focuses on disabling the violating viral RNA and preventing the production of infectious viral protein such as spike protein.

Thus, CRISPR-Cas13 is thought to be a potential therapy for COVID-19 aside from vaccination.

Undeniably, the potential of CRISPR in terms of scientific advances that it catalyses are beneficial for humankind. Still, it raises bioethical questions among the public.

It is a new technology, and there might have consequences and implications that remain unknown. Thus, it requires more research data and validations before practice. By the time of its extensive application, we hope to welcome the golden era that marks the end between human and diseases.

This Privacy Policy (Policy) is an electronic record in the form of an electronic contract formed under the Information Technology Act, 2000 and the Rules made thereunder, the Aadhaar Act, 2016 and Rules and Regulations made thereunder; that require publishing of the privacy policy for the collection, use, storage, transfer, disclosure of Personal Information. This Policy does not require any physical, electronic, or digital signature. This Policy is a legally binding document.

The terms of this Policy will be effective upon your acceptance of the same, by clicking on the "I Accept" tab or by use of the Platform and will govern the relationship between You and AdvanX for your use of the Platform.

This Privacy Policy is for your knowledge, understanding, and agreement as to what information or personal data we collect, why we collect it, and how you can update, manage, and delete your information or personal data. You hereby acknowledge having read and accepted this Privacy Policy. If you don't agree with this policy, you should not register or avail of our services.

We endeavour to respect your privacy regarding any information we may collect while operating the Platform. We are committed to protecting personally identifiable information you may provide us through the Platform. We have adopted this Privacy Policy to explain how we use this information, and under what circumstances we may disclose the information to third parties. We reserve the right to change any of our policies and practices at any time without intimation and your continued use of the Services after we make changes is deemed to be acceptance of those changes, so please check the Privacy Policy periodically for updates.

The Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011 defines personal information as any information that relates to a natural person, which, either directly or indirectly, in combination with other information available or likely to be available with a body corporate, is capable of identifying such person. We collect information or personal data/information to provide better experience and Services to all our users. AdvanX uses this data to underwrite (i.e., assess the risk it will be taking) any loan or product that might be offered through the Platform. The data being asked from you helps us to provide services to you in a robust and user-friendly manner.

3a8082e126